<SEC-DOCUMENT>0001140361-22-026728.txt : 20220722
<SEC-HEADER>0001140361-22-026728.hdr.sgml : 20220722
<ACCEPTANCE-DATETIME>20220722163335
ACCESSION NUMBER:		0001140361-22-026728
CONFORMED SUBMISSION TYPE:	S-8 POS
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20220722
DATE AS OF CHANGE:		20220722
EFFECTIVENESS DATE:		20220722

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ADMA BIOLOGICS, INC.
		CENTRAL INDEX KEY:			0001368514
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				562590442
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-8 POS
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-263345
		FILM NUMBER:		221100291

	BUSINESS ADDRESS:	
		STREET 1:		C/O ADMA BIOLOGICS, INC.
		STREET 2:		465 STATE ROUTE 17
		CITY:			RAMSEY
		STATE:			NJ
		ZIP:			07446
		BUSINESS PHONE:		(201) 478-5552

	MAIL ADDRESS:	
		STREET 1:		C/O ADMA BIOLOGICS, INC.
		STREET 2:		465 STATE ROUTE 17
		CITY:			RAMSEY
		STATE:			NJ
		ZIP:			07446

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	R&R ACQUISITION VI, INC
		DATE OF NAME CHANGE:	20060707
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-8 POS
<SEQUENCE>1
<FILENAME>brhc10039577_s8pos.htm
<DESCRIPTION>S-8 POS
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using Broadridge PROfile 22.7.2.5062
         Copyright 1995 - 2022 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">As filed with the Securities and Exchange Commission on July 22, 2022</div>
    <div><br>
    </div>
    <div style="text-align: right; color: rgb(0, 0, 0); font-weight: bold;">Registration No. 333-204590</div>
    <div style="text-align: right; color: rgb(0, 0, 0); font-weight: bold;">Registration No. 333-220058</div>
    <div style="text-align: right; color: rgb(0, 0, 0); font-weight: bold;">Registration No. 333-224492</div>
    <div style="text-align: right; color: rgb(0, 0, 0); font-weight: bold;">Registration No. 333-229921</div>
    <div style="text-align: right; color: rgb(0, 0, 0); font-weight: bold;">Registration No. 333-237658</div>
    <div style="text-align: right; color: rgb(0, 0, 0); font-weight: bold;">Registration No. 333-254770</div>
    <div style="text-align: right; color: rgb(0, 0, 0); font-weight: bold;">Registration No. 333-263345</div>
    <div style="text-align: right; color: rgb(0, 0, 0); font-weight: bold;"> <br>
    </div>
    <div>
      <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-size: 14pt;">UNITED STATES</div>
    <font style="font-size: 14pt;"> </font>
    <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-size: 14pt;">SECURITIES AND EXCHANGE COMMISSION</div>
    <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-size: 12pt;">WASHINGTON, D.C. 20549</div>
    <div><br>
    </div>
    <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-204590</div>
    <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-220058</div>
    <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-224492</div>
    <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-229921</div>
    <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-237658</div>
    <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-254770</div>
    <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-263345</div>
    <div><br>
    </div>
    <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">REGISTRATION STATEMENT</div>
    <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">UNDER</div>
    <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">THE SECURITIES ACT OF 1933</div>
    <div><br>
    </div>
    <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-size: 24pt;">ADMA BIOLOGICS, INC.</div>
    <div style="text-align: center; color: rgb(0, 0, 0);">(Exact name of registrant as specified in its charter)</div>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" border="0" id="zae3648ccb2d347e695e6f1c3be6b2ade" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

        <tr>
          <td style="width: 49%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Delaware</div>
          </td>
          <td style="width: 2.37%; vertical-align: top;">&#160;</td>
          <td style="width: 49%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">56-2590442</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49%; vertical-align: top;">
            <div style="text-align: center; color: rgb(0, 0, 0);">(State or other jurisdiction of</div>
          </td>
          <td style="width: 2.37%; vertical-align: top;">&#160;</td>
          <td style="width: 49%; vertical-align: top;">
            <div style="text-align: center; color: rgb(0, 0, 0);">(I.R.S. Employer Identification No.)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49%; vertical-align: top;">
            <div style="text-align: center; color: rgb(0, 0, 0);">incorporation or organization)</div>
          </td>
          <td style="width: 2.37%; vertical-align: top;">&#160;</td>
          <td style="width: 49%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 49%; vertical-align: top;">&#160;</td>
          <td style="width: 2.37%; vertical-align: top;">&#160;</td>
          <td style="width: 49%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 49%; vertical-align: top;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">465 State Route 17</div>
          </td>
          <td style="width: 2.37%; vertical-align: top;">&#160;</td>
          <td style="width: 49%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 49%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Ramsey, New Jersey</div>
          </td>
          <td style="width: 2.37%; vertical-align: top;">&#160;</td>
          <td style="width: 49%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">07446</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49%; vertical-align: top;">
            <div style="text-align: center; color: rgb(0, 0, 0);">(Address of Principal Executive Offices)</div>
          </td>
          <td style="width: 2.37%; vertical-align: top;">&#160;</td>
          <td style="width: 49%; vertical-align: top;">
            <div style="text-align: center; color: rgb(0, 0, 0);">(Zip Code)</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">AMENDED AND RESTATED ADMA BIOLOGICS, INC. 2014 OMNIBUS INCENTIVE COMPENSATION PLAN</div>
    <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">ADMA BIOLOGICS, INC. 2022 EQUITY COMPENSATION PLAN</div>
    <div style="text-align: center; color: rgb(0, 0, 0);">(Full title of the plan)</div>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" border="0" id="z12b143e23e4f45cf8ebb5f607dfd8182" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

        <tr>
          <td style="width: 49%; vertical-align: top;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Adam S. Grossman</div>
          </td>
          <td style="width: 2.39%; vertical-align: top;">&#160;</td>
          <td style="width: 49%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 49%; vertical-align: top;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">President and Chief Executive Officer</div>
          </td>
          <td style="width: 2.39%; vertical-align: top;">&#160;</td>
          <td style="width: 49%; vertical-align: top;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">David C. Schwartz, Esq.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49%; vertical-align: top;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">ADMA Biologics, Inc.</div>
          </td>
          <td style="width: 2.39%; vertical-align: top;">&#160;</td>
          <td style="width: 49%; vertical-align: top;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Morgan, Lewis &amp; Bockius LLP</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49%; vertical-align: top;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">465 State Route 17</div>
          </td>
          <td style="width: 2.39%; vertical-align: top;">&#160;</td>
          <td style="width: 49%; vertical-align: top;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">502 Carnegie Center</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49%; vertical-align: top;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Ramsey, New Jersey 07446</div>
          </td>
          <td style="width: 2.39%; vertical-align: top;">&#160;</td>
          <td style="width: 49%; vertical-align: top;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Princeton, New Jersey 08540</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">(201) 478-5552</div>
          </td>
          <td style="width: 2.39%; vertical-align: top;">&#160;</td>
          <td style="width: 49%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">&#160;(609) 919-6600</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49%; vertical-align: top;">
            <div style="text-align: center; color: rgb(0, 0, 0);">(Name, address, telephone number,</div>
          </td>
          <td style="width: 2.39%; vertical-align: top;">&#160;</td>
          <td style="width: 49%; vertical-align: top;">
            <div style="text-align: center; color: rgb(0, 0, 0);">(With copies to)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49%; vertical-align: top;">
            <div style="text-align: center; color: rgb(0, 0, 0);">including area code, of agent for service)</div>
          </td>
          <td style="width: 2.39%; vertical-align: top;">&#160;</td>
          <td style="width: 49%; vertical-align: top;">&#160;</td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 18pt; color: rgb(0, 0, 0);">Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth
      company.&#160; See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</div>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" border="0" id="zcd27dfc4bbc846e0975b0aae81221d3f" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

        <tr>
          <td style="width: 20%; vertical-align: top;">
            <div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Large accelerated filer &#9744;</div>
          </td>
          <td style="width: 20%; vertical-align: top;">
            <div style="text-align: center; color: rgb(0, 0, 0);">Accelerated filer &#9744;</div>
          </td>
          <td style="width: 20%; vertical-align: top;">
            <div style="text-align: center; color: rgb(0, 0, 0);">Non-accelerated filer &#9746;</div>
          </td>
          <td style="width: 20%; vertical-align: top;">
            <div style="text-align: center; color: rgb(0, 0, 0);">Smaller reporting company &#9746;</div>
          </td>
          <td style="width: 20.01%; vertical-align: top;">
            <div style="text-align: center; color: rgb(0, 0, 0);">Emerging growth company &#9744;</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 18pt; color: rgb(0, 0, 0);">If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial
      accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.&#160; &#9744;</div>
    <div><br>
    </div>
    <div>
      <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">EXPLANATORY NOTE</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">ADMA Biologics, Inc., a Delaware corporation (the &#8220;<u>Registrant</u>&#8221;), previously filed with the Securities and Exchange Commission (the &#8220;<u>Commission</u>&#8221;) the following registration statements on
      Form S-8 (collectively, the &#8220;<u>Registration Statements</u>&#8221;) on the dates set forth below to register shares of the Registrant&#8217;s common stock, $0.0001 par value per share (the &#8220;<u>Common Stock</u>&#8221;) under the Amended and Restated ADMA Biologics,
      Inc. 2014 Omnibus Incentive Compensation Plan, as amended (the &#8220;<u>2014 Plan</u>&#8221;), as set forth below:</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">File No. 333-263345 on March 7, 2022 to register 7,832,552 shares of Common Stock;</div>
    <div style="text-align: justify; text-indent: 36pt;">File No. 333-254770 on March 26, 2021 to register 3,491,134 shares of Common Stock;</div>
    <div style="text-align: justify; text-indent: 36pt;">File No. 333-237658 on April 13, 2020 to register 2,372,734 shares of Common Stock;</div>
    <div style="text-align: justify; text-indent: 36pt;">File No. 333-229921 on February 27, 2019 to register 1,854,122 shares of Common Stock;</div>
    <div style="text-align: justify; text-indent: 36pt;">File No. 333-224492 on April 27, 2018 to register 1,812,666 shares of Common Stock;</div>
    <div style="text-align: justify; text-indent: 36pt;">File No. 333-220058 on August 18, 2017 to register 2,000,000 shares of Common Stock; and</div>
    <div style="text-align: justify; text-indent: 36pt;">File No. 333-204590 on May 29, 2015 to register 1,600,000 shares of Common Stock.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">Pursuant to the Registration Statements, an aggregate of 20,963,208 shares of Common Stock were registered for issuance from time to time under the 2014 Plan.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">On June 21, 2022 (the &#8220;<u>Effective Date</u>&#8221;), the Registrant&#8217;s stockholders approved the ADMA Biologics, Inc. 2022 Equity Compensation Plan (the &#8220;<u>2022 Plan</u>&#8221;). Following the approval of the
      2022 Plan, no future awards will be granted under the 2014 Plan and (i) any shares of Common Stock that remained available for grants under the 2014 Plan or (ii) any shares any shares of Common Stock subject to outstanding grants under the 2014 Plan
      that terminate, expire or are canceled, forfeited, exchanged or surrendered without having been exercised, vested or paid under the 2014 Plan after the Effective Date of the 2022 Plan shall be available for issuance under the 2022 Plan (as disclosed
      in the Registrant&#8217;s Definitive Proxy Statement on Schedule 14A, filed with the Securities and Exchange Commission on April 28, 2022, there were 13,722,164 shares of Common Stock underlying existing equity awards under the 2014 Plan as of April
      25,2022) (the shares described in clauses (i) and (ii) collectively, the &#8220;<u>Rollover Shares</u>&#8221;).</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">The Registrant is filing this Post-Effective Amendment to the Registration Statements pursuant to (i) the Securities Act of 1933, as amended (the &#8220;<u>Securities Act</u>&#8221;), (ii) the undertaking in
      Item 512(a)(1)(iii) of Regulation S-K, which requires the Registrant to disclose a material change in the plan of distribution as it was originally disclosed in the Registration Statements, and (iii) the Securities Act Forms Compliance and Disclosure
      Interpretation Question 126.43, reflecting the interpretive position of the Division of Corporation Finance of the Commission, to amend the Registration Statements to also cover the registration of (a) up to 5,714,620 Rollover Shares (which reflects
      the number of shares of Common Stock that remained available for grants under the 2014 Plan as of the Effective Date) and (b) Rollover Shares subject to awards outstanding as of the Effective Date under the 2014 Plan (to the extent such Rollover
      Shares are, or become no longer issuable under the 2014 Plan and instead are, or become, issuable under the 2022 Plan). No additional securities are being registered by this Post-Effective Amendment. For the avoidance of doubt, this Post&#8209;Effective
      Amendment will not cause the Registration Statements to cover the registration of any additional shares of Common Stock that may be offered under the 2022 Plan that were not previously issuable under the 2014 Plan.</div>
    <div><br>
    </div>
    <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">PART I</div>
    <div><br>
    </div>
    <div style="text-align: center; font-weight: bold;">INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS</div>
    <div>&#160;</div>
    <table cellspacing="0" cellpadding="0" id="zcdeb0814dffb4e3da968eed233ff675a" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 72pt; vertical-align: top; font-weight: bold;">Item 1.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;">Plan Information.*</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z0a2d4aa8c8a94bb4a1343bfb6f148fff" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 72pt; vertical-align: top; font-weight: bold;">Item 2.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;">Registrant Information and Employee Plan Annual Information.*</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div style="text-align: justify;">
      <hr noshade="noshade" align="left" style="background-color: #000000; border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none; margin: 0px auto 0px 0px; height: 2px; width: 15%; color: #000000; text-align: left;"></div>
    <table cellspacing="0" cellpadding="0" id="za7a8f35287c14b77aec8aaa5500dd830" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; vertical-align: top;">*</td>
          <td style="width: auto; vertical-align: top;">
            <div style="text-align: justify;">The document(s) containing the information specified in Part I will be delivered in accordance with Rule 428(b)(1) under the Securities Act. Such documents are not required to be, and are not, filed with the
              Commission, either as part of this Post-Effective Amendment or as prospectuses or prospectus supplements pursuant to Rule 424 under the Securities Act. These documents, and the documents incorporated by reference in this Post-Effective
              Amendment pursuant to Item 3 of Part II of this Form S-8, taken together, constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: center; font-weight: bold;">PART II</div>
    <div>&#160;</div>
    <div style="text-align: center; font-weight: bold;">INFORMATION REQUIRED IN THE REGISTRATION STATEMENT</div>
    <div>&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z731348b4e60945ee8b19750d008481d8" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 72pt; vertical-align: top; font-weight: bold;">Item 3.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;">Incorporation of Documents by Reference.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">The following documents, which have been previously filed by the <font style="color: rgb(0, 0, 0);">Registrant</font> with the Commission pursuant to the Securities Exchange Act of 1934, as amended
      (the &#8220;<u>Exchange Act</u>&#8221;) are hereby incorporated herein by reference and shall be deemed to be a part of this Post-Effective Amendment:</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">(1)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The <font style="color: rgb(0, 0, 0);">Registrant&#8217;s</font> Annual Report on Form 10-K for the year ended December 31, 2021, filed with the Commission on <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1368514/000114036122011030/brhc10035480_10k.htm">March 24, 2022</a> (including the portions of the Registrant's Definitive Proxy Statement on Schedule 14A filed with the Commission on <a href="https://www.sec.gov/Archives/edgar/data/1368514/000114036122016578/ny20003524x2_def14a.htm">April 28, 2022</a> that are incorporated by reference therein);&#160;</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">(2)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended March 31, 2022, filed with the Commission on <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1368514/000114036122018668/brhc10037445_10q.htm">May 11, 2022</a>;</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">(3)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The <font style="color: rgb(0, 0, 0);">Registrant&#8217;s Current Reports on Form 8-K filed with the Commission on <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1368514/000114036122001782/brhc10032849_8k.htm">January 18, 2022</a>, <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1368514/000114036122008174/brhc10034851_8k.htm">March 7, 2022</a>,
        <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1368514/000114036122008654/brhc10035009_8k.htm">March 9, 2022</a>, <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1368514/000114036122011213/brhc10035702_8k.htm">March 25, 2022</a>,
        <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1368514/000114036122022769/brhc10038698_8k.htm">June 13, 2022</a>, <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1368514/000114036122023666/brhc10038967_8k.htm">June 21, 2022</a>
        and <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1368514/000114036122024139/brhc10039148_8k.htm">June 27, 2022</a> (provided that any portions of such reports that are deemed furnished and</font> not filed pursuant to instructions to
      Form 8-K shall not be incorporated by reference into the Registration Statements); and</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">(4)&#160;&#160;&#160;&#160; &#160; &#160; The description of Common Stock set forth in Exhibit 4.11 to the <font style="color: rgb(0, 0, 0);">Registrant&#8217;s</font> Annual Report on Form 10-K filed with the Commission on <a href="https://www.sec.gov/Archives/edgar/data/1368514/000114036122011030/brhc10035480_ex4-11.htm">March 24, 2022</a> pursuant to Section 12(b) of the Exchange Act, including any amendment or report filed for the purpose of updating such
      description.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">In addition, all documents that the <font style="color: rgb(0, 0, 0);">Registrant</font> files pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act subsequent to the effective date of
      this Post-Effective Amendment (except for any portions of the <font style="color: rgb(0, 0, 0);">Registrant&#8217;s</font> Current Reports on Form 8-K furnished pursuant to Item 2.02 or Item 7.01 thereof and any corresponding exhibits thereto not filed
      with the Commission), but prior to the filing of a post-effective amendment to the Registration Statements indicating that all securities offered hereby have been sold or which deregisters all securities then remaining unsold shall be deemed to be
      incorporated by reference in the Registration Statements and to be a part thereof from the date of filing such documents.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">For purposes of the Registration Statements, any document or statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or
      superseded to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such document or statement in such document. Any such
      statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of the Registration Statements.</div>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="zf9c006ff8fa346c692aa11cb3ebb006d" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 72pt; vertical-align: top; font-weight: bold;">Item 4.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;">Description of Securities.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">Not applicable.</div>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="zeaf04dda4daa4c27bbb6323706bb3344" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 72pt; vertical-align: top; font-weight: bold;">Item 5.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;">Interests of Named Experts and Counsel.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">Not applicable.</div>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="z5dc916c490664b248d9a1848a0605381" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 72pt; vertical-align: top; font-weight: bold;">Item 6.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;">Indemnification of Directors and Officers.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">Section 145 of the DGCL provides, generally, that a corporation shall have the power to indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or
      completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of the corporation) by reason of the fact that such person is or was a director, officer, employee or agent of the
      corporation against all expenses, judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with such action, suit or proceeding if such person acted in good faith and in a manner such person
      reasonably believed to be in or not opposed to the best interests of the corporation and, with respect to any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful. A corporation may similarly indemnify
      such person for expenses actually and reasonably incurred by such person in connection with the defense or settlement of any action or suit by or in the right of the corporation, provided that such person acted in good faith and in a manner he or she
      reasonably believed to be in or not opposed to the best interests of the corporation, and, in the case of claims, issues and matters as to which such person shall have been adjudged liable to the corporation, provided that a court shall have
      determined, upon application, that, despite the adjudication of liability but in view of all of the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which such court shall deem proper.</div>
    <div>&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">In accordance with Section 102(b)(7) of the DGCL, the Registrant&#8217;s Second Amended and Restated Certificate of Incorporation (the &#8220;<u>Charter</u>&#8221;) provides that a director will not be personally
      liable to the Registrant or its stockholders for monetary damages for breach of fiduciary duty as a director, except to the extent such exemption from liability or limitation thereof is not permitted under the DGCL. No such provision shall eliminate
      or limit the liability of a director for any act or omission occurring prior to the date when such provision became effective. Accordingly, these provisions will have no effect on the availability of equitable remedies such as an injunction or
      rescission based on a director&#8217;s breach of his or her duty of care.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">The Charter provides that the Registrant will indemnify its present and former directors and officers to the maximum extent permitted by the DGCL and that such indemnification will not be exclusive
      of any other rights to which those seeking indemnification may have or hereafter acquire under any statute, provision of the Charter, the Registrant&#8217;s bylaws, agreement, vote of stockholders or disinterested directors or otherwise.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">The Registrant has entered into, and expects to continue to enter into, customary indemnification arrangements with each of its current directors and executive officers. These arrangements require
      the Registrant to indemnify these individuals to the fullest extent permitted under Delaware law against liabilities that may arise by reason of their service to the Registrant, and to advance expenses incurred as a result of any proceeding against
      them as to which they could be indemnified. The Registrant also intends to enter into indemnification arrangements with future directors and executive officers.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">See also the undertakings set out in response to Item 9 hereof.</div>
    <div>&#160;</div>
    <table cellspacing="0" cellpadding="0" id="zefb0d5eb8ad24c1aa32def22fc9c4478" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 72pt; vertical-align: top; font-weight: bold;">Item 7.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;">Exemption from Registration Claimed.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div style="text-indent: 36pt;">Not applicable.</div>
    <div>&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z9820f35f2cef4518994950a743121e20" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 72pt; vertical-align: top; font-weight: bold;">Item 8.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;">Exhibits.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">The Registrant hereby files the exhibits set forth below:</div>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" border="0" id="z25f6806c0dae495189341660d7b257f9" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);">

        <tr>
          <td style="width: 10.2%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; text-indent: -2.7pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: bold;">Exhibit Number</div>
          </td>
          <td style="width: 2%; vertical-align: bottom;">&#160;</td>
          <td style="width: 88%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Description of Exhibit</div>
          </td>
        </tr>
        <tr>
          <td style="width: 10.2%; vertical-align: top;">&#160;</td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 88%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 10.2%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: justify; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);"><a href="https://www.sec.gov/Archives/edgar/data/1368514/000119380519000774/e618626_ex3-1.htm">4.1</a></div>
          </td>
          <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>
          <td style="width: 88%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: justify; color: rgb(0, 0, 0);">Second Amended and Restated Certificate of Incorporation of the ADMA Biologics, Inc. (incorporated herein by reference to Exhibit 3.1 to the Registrant&#8217;s Current Report on Form 8-K, filed
              with the Commission on August 23, 2019).</div>
          </td>
        </tr>
        <tr>
          <td style="width: 10.2%; vertical-align: top;">&#160;</td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 88%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 10.2%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: justify; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);"><a href="https://www.sec.gov/Archives/edgar/data/1368514/000119380521000749/e620651_ex3-1.htm">4.2</a></div>
          </td>
          <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>
          <td style="width: 88%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: justify; color: rgb(0, 0, 0);">Certificate of Amendment of the Second Amended and Restated Certificate of Incorporation of ADMA Biologics, Inc., dated as of May 27, 2021 (incorporated by reference to Exhibit 3.1 to the
              Registrant&#8217;s Current Report on Form 8-K filed with the Commission on May 28, 2021).</div>
          </td>
        </tr>
        <tr>
          <td style="width: 10.2%; vertical-align: top;">&#160;</td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 88%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 10.2%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: justify; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);"><a href="https://www.sec.gov/Archives/edgar/data/1368514/000119380516004084/e615468_ex3-1.htm">4.3</a></div>
          </td>
          <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>
          <td style="width: 88%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: justify; color: rgb(0, 0, 0);">Amended and Restated Bylaws (incorporated herein by reference to Exhibit 3.1 to the Registrant&#8217;s Current Report on Form 8-K, filed with the Commission on October 7, 2016).</div>
          </td>
        </tr>
        <tr>
          <td style="width: 10.2%; vertical-align: top;">&#160;</td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 88%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 10.2%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: justify; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);"><a href="brhc10039577_ex5-1.htm">5.1</a></div>
          </td>
          <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>
          <td style="width: 88%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: justify; color: rgb(0, 0, 0);">Opinion of Morgan, Lewis and Bockius LLP, counsel for the Registrant, regarding the legal validity of the shares of Common Stock being registered on this Registration Statement (filed
              herewith).</div>
          </td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 10.2%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 2%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 88%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 10.2%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: justify; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);"><a href="https://www.sec.gov/Archives/edgar/data/1368514/000119380517001506/e616485_ex10-1.htm">10.1</a></div>
          </td>
          <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>
          <td style="width: 88%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: justify; color: rgb(0, 0, 0);">Amended and Restated ADMA Biologics, Inc. 2014 Omnibus Incentive Compensation Plan (incorporated herein by reference to Exhibit 10.1 to the Registrant&#8217;s Registration Statement on Form S&#8209;8
              filed on August 18, 2017).</div>
          </td>
        </tr>
        <tr>
          <td style="width: 10.2%; vertical-align: top;">&#160;</td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 88%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 10.2%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: justify; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);"><a href="https://www.sec.gov/Archives/edgar/data/1368514/000114036122023666/brhc10038967_ex10-1.htm">10.2</a></div>
          </td>
          <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>
          <td style="width: 88%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: justify; color: rgb(0, 0, 0);">ADMA Biologics, Inc. 2022 Equity Compensation Plan (incorporated herein by reference to Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K filed with the Commission on June 21,
              2022).</div>
          </td>
        </tr>
        <tr>
          <td style="width: 10.2%; vertical-align: top;">&#160;</td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 88%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 10.2%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: justify; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);"><a href="brhc10039577_ex5-1.htm">23.1</a></div>
          </td>
          <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>
          <td style="width: 88%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: justify; color: rgb(0, 0, 0);">Consent of Morgan, Lewis and Bockius LLP (contained in Exhibit 5.1).</div>
          </td>
        </tr>
        <tr>
          <td style="width: 10.2%; vertical-align: top;">&#160;</td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 88%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 10.2%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: justify; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);"><a href="brhc10039577_ex23-2.htm">23.2</a></div>
          </td>
          <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>
          <td style="width: 88%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: justify;">Consent of CohnReznick LLP, the Registrant&#8217;s Independent Registered Public Accounting Firm <font style="color: rgb(0, 0, 0);">(filed herewith).</font></div>
          </td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 10.2%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 2%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 88%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 10.2%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: justify; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);"><a href="#SIGNATURES">24.1</a></div>
          </td>
          <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>
          <td style="width: 88%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: justify;">Power of Attorney (included on signature page).</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <table cellspacing="0" cellpadding="0" id="z2f7efa4faf7347b19b5215cc0bdd16c9" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 72pt; vertical-align: top; font-weight: bold;">Item 9.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;">Undertakings.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div>
      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zadaa67784cf04de58b45a9e420aa66ac" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

            <tr style="vertical-align: top;">
              <td style="width: 18pt;">&#160;</td>
              <td style="vertical-align: top; width: 18pt;">
                <div><font style="color: rgb(0, 0, 0);">(a)</font></div>
              </td>
              <td style="vertical-align: top; width: auto;">
                <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);">The undersigned Registrant hereby undertakes:</font></div>
              </td>
            </tr>

        </table>
      </div>
    </div>
    <div>
      <div><br>
      </div>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z3f41c8add2ea46578553a826c1186794" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">1.</td>
            <td style="width: auto; vertical-align: top;">
              <div style="color: rgb(0, 0, 0); text-align: justify;">To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:</div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <div><br>
      </div>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="zc30c34309aec4be38dc5bb37a5d83ce3" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 72pt;">&#160;</td>
            <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">i.</td>
            <td style="vertical-align: top;">
              <div style="color: rgb(0, 0, 0); text-align: justify;">To include any prospectus required by Section 10(a)(3) of the Securities Act;</div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <div><br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" id="z6a10f55ee13c447eaf8af03a3aad810e" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 72pt;">&#160;</td>
              <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">ii.</td>
              <td style="vertical-align: top;">
                <div style="color: rgb(0, 0, 0); text-align: justify;">To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually
                  or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of
                  securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b)
                  if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the &#8220;Calculation of Registration Fee&#8221; table in the effective registration statement.</div>
              </td>
            </tr>

        </table>
      </div>
    </div>
    <div>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z62d82d6df28e474c89a404fa7e875dba" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 72pt;">&#160;</td>
            <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">iii.</td>
            <td style="vertical-align: top;">
              <div style="color: rgb(0, 0, 0); text-align: justify;">To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the
                registration statement;</div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <div><br>
      </div>
    </div>
    <div>
      <div style="text-align: justify; color: rgb(0, 0, 0);"><font style="font-style: italic;">Provided, however,</font> that paragraphs (a)(i) and (a)(ii) do not apply if the information required to be included in a post-effective amendment by those
        paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the registration statement.</div>
      <div><br>
      </div>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z095c1036bb444e65af7fbae01910bdbe" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">2.</td>
            <td style="width: auto; vertical-align: top;">
              <div style="color: rgb(0, 0, 0); text-align: justify;">That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the
                securities offered herein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <div><br>
      </div>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z85d62c2a5d5d4628aa74d9ccfba59a54" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">3.</td>
            <td style="width: auto; vertical-align: top;">
              <div style="color: rgb(0, 0, 0); text-align: justify;">To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.</div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <div><br>
      </div>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z7b8ba82e807543cd9afe9b7f4e0c0865" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">4.</td>
            <td style="width: auto; vertical-align: top;">
              <div style="color: rgb(0, 0, 0); text-align: justify;">That, for the purpose of determining liability of the Registrant under the Securities Act to any purchaser in the initial distribution of the securities, the undersigned Registrant
                undertakes that in a primary offering of securities of the undersigned Registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or
                sold to such purchaser by means of any of the following communications, the undersigned Registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:</div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <div><br>
      </div>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z6fbbf014d75148309787c628fda80d13" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 72pt;">&#160;</td>
            <td style="width: 18pt; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">i.</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="color: rgb(0, 0, 0); text-align: justify;">Any preliminary prospectus or prospectus of the undersigned Registrant relating to the offering required to be filed pursuant to Rule 424,</div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <div><br>
      </div>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z3a46ae822f474ee68f08bd1e64042fee" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 72pt;">&#160;</td>
            <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">ii.</td>
            <td style="width: auto; vertical-align: top;">
              <div style="color: rgb(0, 0, 0); text-align: justify;">Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned Registrant or used or referred to by the undersigned Registrant,</div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <div><br>
      </div>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z2cc840603aa94ac8885e85a7863abb6a" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 72pt;">&#160;</td>
            <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">iii.</td>
            <td style="width: auto; vertical-align: top;">
              <div style="color: rgb(0, 0, 0); text-align: justify;">The portion of any other free writing prospectus relating to the offering containing material information about the undersigned Registrant or its securities provided by or on behalf of
                the undersigned Registrant, and</div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <div><br>
      </div>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z88a0eb84603a42b8a6c6aee293ef807f" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 72pt;">&#160;</td>
            <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">iv.</td>
            <td style="width: auto; vertical-align: top;">
              <div style="color: rgb(0, 0, 0); text-align: justify;">Any other communication that is an offer in the offering made by the undersigned Registrant to the purchaser.</div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <div style="text-align: justify;"><br>
      </div>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z84cfc74da1fb4481a3fd6c85ae54f3f9" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">5.</td>
            <td style="width: auto; vertical-align: top;">
              <div style="color: rgb(0, 0, 0); text-align: justify;">That, for purposes of determining any liability under the Securities Act, each filing of the Registrant&#8217;s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act
                (and, where applicable, each filing of an employee benefit plan&#8217;s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration
                statement relating to the securities offered herein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <div><br>
      </div>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z807cfb01e00947e2b0d30a981406f1a2" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">(b)</td>
            <td style="width: auto; vertical-align: top;">
              <div style="color: rgb(0, 0, 0); text-align: justify;">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing
                provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for
                indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is
                asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court
                of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.</div>
            </td>
          </tr>

      </table>
    </div>
    <div><br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: center; font-weight: bold;">SIGNATURES<a name="SIGNATURES"><!--Anchor--></a></div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8
      and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Ramsey, State of New Jersey, on this 22<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">nd</sup>
      day of July, 2022.</div>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" border="0" id="z40a313e7dc924b2eab36ce5df1d1419e" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="vertical-align: top;" colspan="2">
            <div style="text-align: justify; color: rgb(0, 0, 0); font-weight: bold;">ADMA Biologics, Inc.</div>
            <div style="text-align: justify; color: rgb(0, 0, 0);">(Registrant)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="vertical-align: top;" colspan="2">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 3%; vertical-align: top;">
            <div style="color: rgb(0, 0, 0);">By:</div>
          </td>
          <td style="width: 47%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="color: rgb(0, 0, 0);">/s/ Brian Lenz</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 3%; vertical-align: top;">&#160;</td>
          <td style="width: 47%; vertical-align: top;">
            <div style="color: rgb(0, 0, 0);">Name: Brian Lenz</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 3%; vertical-align: top;">&#160;</td>
          <td style="width: 47%; vertical-align: top;">
            <div style="color: rgb(0, 0, 0);">Title: Executive Vice President and Chief Financial Officer</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-align: center; font-weight: bold;">POWER OF ATTORNEY</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">KNOW BY ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Adam S. Grossman and Brian Lenz, and each of them, the undersigned&#8217;s true and lawful
      attorneys-in-fact and agents, with full power of substitution and revocation, for and in the undersigned&#8217;s name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration
      Statement on Form S-8 (this &#8220;<u>Registration Statement</u>&#8221;) and any registration statement filed pursuant to Rule 462(b) under the Securities Act of 1933, as amended (the &#8220;<u>Securities Act</u>&#8221;), and to file the same, with all exhibits thereto, and
      other documents in connection therewith, with the Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done, as fully to
      all intents and purposes as the undersigned might or could do in person, hereby ratify and confirming all that said attorneys-in-fact and agents or any of them, or their or his substitutes, may lawfully do or cause to be done by virtue thereof.</div>
    <div style="text-align: justify; text-indent: 36pt;"> <br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">Pursuant to the requirements of the Securities Act, this Registration Statement has been signed below by the following persons on behalf of the Registrant and in the capacities indicated on the date
      listed below.</div>
    <div style="text-align: justify;"> <br>
    </div>
    <table cellspacing="0" cellpadding="0" border="0" id="z94afa21a7c50438e90f0e8ae956750e6" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

        <tr>
          <td style="width: 30%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: justify; font-weight: bold;">Signature</div>
          </td>
          <td style="width: 2%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>
          <td style="width: 48%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; font-weight: bold;">Capacity</div>
          </td>
          <td colspan="1" style="width: 2%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 18%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; font-weight: bold;">Date</div>
          </td>
        </tr>
        <tr>
          <td style="width: 30%; vertical-align: top;">&#160;</td>
          <td style="width: 2%; vertical-align: top;" colspan="1">&#160;</td>
          <td style="width: 48%; vertical-align: top;">&#160;</td>
          <td colspan="1" style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 18%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 30%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
            <div>/s/ Adam S. Grossman</div>
          </td>
          <td style="width: 2%; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
          <td style="width: 48%; vertical-align: top; padding-bottom: 2px;">
            <div>President and Chief Executive Officer, Director</div>
          </td>
          <td colspan="1" style="width: 2%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
          <td style="width: 18%; vertical-align: top; padding-bottom: 2px;">
            <div style="text-align: justify;">July 22, 2022</div>
          </td>
        </tr>
        <tr>
          <td style="width: 30%; vertical-align: top;">
            <div style="text-align: justify; margin-left: 9pt;">Adam S. Grossman</div>
          </td>
          <td style="width: 2%; vertical-align: top;" colspan="1">&#160;</td>
          <td style="width: 48%; vertical-align: top;">
            <div>(Principal Executive Officer)</div>
          </td>
          <td colspan="1" style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 18%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 30%; vertical-align: top;">&#160;</td>
          <td style="width: 2%; vertical-align: top;" colspan="1">&#160;</td>
          <td style="width: 48%; vertical-align: top;">&#160;</td>
          <td colspan="1" style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 18%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 30%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
            <div>/s/ Brian Lenz</div>
          </td>
          <td style="width: 2%; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
          <td style="width: 48%; vertical-align: top; padding-bottom: 2px;">
            <div>Executive Vice President and Chief Financial Officer</div>
          </td>
          <td colspan="1" style="width: 2%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
          <td style="width: 18%; vertical-align: top; padding-bottom: 2px;">
            <div style="text-align: justify;">July 22, 2022</div>
          </td>
        </tr>
        <tr>
          <td style="width: 30%; vertical-align: top;">
            <div style="text-align: justify; margin-left: 9pt;">Brian Lenz</div>
          </td>
          <td style="width: 2%; vertical-align: top;" colspan="1">&#160;</td>
          <td style="width: 48%; vertical-align: top;">
            <div>(Principal Financial Officer and Principal Accounting Officer)</div>
          </td>
          <td colspan="1" style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 18%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 30%; vertical-align: top;">&#160;</td>
          <td style="width: 2%; vertical-align: top;" colspan="1">&#160;</td>
          <td style="width: 48%; vertical-align: top;">&#160;</td>
          <td colspan="1" style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 18%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 30%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
            <div>/s/ Steven A. Elms</div>
          </td>
          <td style="width: 2%; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
          <td style="width: 48%; vertical-align: top; padding-bottom: 2px;">
            <div>Chairman of the Board of Directors</div>
          </td>
          <td colspan="1" style="width: 2%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
          <td style="width: 18%; vertical-align: top; padding-bottom: 2px;">
            <div style="text-align: justify;">July 22, 2022</div>
          </td>
        </tr>
        <tr>
          <td style="width: 30%; vertical-align: top;">
            <div style="text-align: justify; margin-left: 9pt;">Steven A. Elms</div>
          </td>
          <td style="width: 2%; vertical-align: top;" colspan="1">&#160;</td>
          <td style="width: 48%; vertical-align: top;">&#160;</td>
          <td colspan="1" style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 18%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 30%; vertical-align: top;">&#160;</td>
          <td style="width: 2%; vertical-align: top;" colspan="1">&#160;</td>
          <td style="width: 48%; vertical-align: top;">&#160;</td>
          <td colspan="1" style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 18%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 30%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
            <div>/s/ Dr. Jerrold B. Grossman</div>
          </td>
          <td style="width: 2%; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
          <td style="width: 48%; vertical-align: top; padding-bottom: 2px;">
            <div>Vice Chairman of the Board of Directors</div>
          </td>
          <td colspan="1" style="width: 2%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
          <td style="width: 18%; vertical-align: top; padding-bottom: 2px;">
            <div style="text-align: justify;">July 22, 2022</div>
          </td>
        </tr>
        <tr>
          <td style="width: 30%; vertical-align: top;">
            <div style="text-align: justify; margin-left: 9pt;">Dr. Jerrold B. Grossman</div>
          </td>
          <td style="width: 2%; vertical-align: top;" colspan="1">&#160;</td>
          <td style="width: 48%; vertical-align: top;">&#160;</td>
          <td colspan="1" style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 18%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 30%; vertical-align: top;">&#160;</td>
          <td style="width: 2%; vertical-align: top;" colspan="1">&#160;</td>
          <td style="width: 48%; vertical-align: top;">&#160;</td>
          <td colspan="1" style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 18%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 30%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div>/s/ Martha J. Demski</div>
          </td>
          <td style="width: 2%; vertical-align: top; padding-bottom: 2px;" colspan="1">&#160;</td>
          <td style="width: 48%; vertical-align: top; padding-bottom: 2px;">
            <div style="text-align: justify;">Director</div>
          </td>
          <td colspan="1" style="width: 2%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
          <td style="width: 18%; vertical-align: top; padding-bottom: 2px;">
            <div style="text-align: justify;">July 22, 2022</div>
          </td>
        </tr>
        <tr>
          <td style="width: 30%; vertical-align: top;">
            <div style="text-align: justify; margin-left: 9pt;">Martha J. Demski</div>
          </td>
          <td style="width: 2%; vertical-align: top;" colspan="1">&#160;</td>
          <td style="width: 48%; vertical-align: top;">&#160;</td>
          <td colspan="1" style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 18%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 30%; vertical-align: top;">&#160;</td>
          <td style="width: 2%; vertical-align: top;" colspan="1">&#160;</td>
          <td style="width: 48%; vertical-align: top;">&#160;</td>
          <td colspan="1" style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 18%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 30%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div>/s/ Bryant E. Fong</div>
          </td>
          <td style="width: 2%; vertical-align: top; padding-bottom: 2px;" colspan="1">&#160;</td>
          <td style="width: 48%; vertical-align: top; padding-bottom: 2px;">
            <div style="text-align: justify;">Director</div>
          </td>
          <td colspan="1" style="width: 2%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
          <td style="width: 18%; vertical-align: top; padding-bottom: 2px;">
            <div style="text-align: justify;">July 22, 2022</div>
          </td>
        </tr>
        <tr>
          <td style="width: 30%; vertical-align: top;">
            <div style="text-align: justify; margin-left: 9pt;">Bryant E. Fong</div>
          </td>
          <td style="width: 2%; vertical-align: top;" colspan="1">&#160;</td>
          <td style="width: 48%; vertical-align: top;">&#160;</td>
          <td colspan="1" style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 18%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 30%; vertical-align: top;">&#160;</td>
          <td style="width: 2%; vertical-align: top;" colspan="1">&#160;</td>
          <td style="width: 48%; vertical-align: top;">&#160;</td>
          <td colspan="1" style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 18%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 30%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div>/s/ Lawrence P. Guiheen</div>
          </td>
          <td style="width: 2%; vertical-align: top; padding-bottom: 2px;" colspan="1">&#160;</td>
          <td style="width: 48%; vertical-align: top; padding-bottom: 2px;">
            <div style="text-align: justify;">Director</div>
          </td>
          <td colspan="1" style="width: 2%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
          <td style="width: 18%; vertical-align: top; padding-bottom: 2px;">
            <div style="text-align: justify;">July 22, 2022</div>
          </td>
        </tr>
        <tr>
          <td style="width: 30%; vertical-align: top;">
            <div style="text-align: justify; margin-left: 9pt;">Lawrence P. Guiheen</div>
          </td>
          <td style="width: 2%; vertical-align: top;" colspan="1">&#160;</td>
          <td style="width: 48%; vertical-align: top;">&#160;</td>
          <td colspan="1" style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 18%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 30%; vertical-align: top;">&#160;</td>
          <td style="width: 2%; vertical-align: top;" colspan="1">&#160;</td>
          <td style="width: 48%; vertical-align: top;">&#160;</td>
          <td colspan="1" style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 18%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 30%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div>/s/ Young T. Kwon</div>
          </td>
          <td style="width: 2%; vertical-align: top; padding-bottom: 2px;" colspan="1">&#160;</td>
          <td style="width: 48%; vertical-align: top; padding-bottom: 2px;">
            <div style="text-align: justify;">Director</div>
          </td>
          <td colspan="1" style="width: 2%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
          <td style="width: 18%; vertical-align: top; padding-bottom: 2px;">
            <div style="text-align: justify;">July 22, 2022</div>
          </td>
        </tr>
        <tr>
          <td style="width: 30%; vertical-align: top;">
            <div style="text-align: justify; margin-left: 9pt;">Young T. Kwon</div>
          </td>
          <td style="width: 2%; vertical-align: top;" colspan="1">&#160;</td>
          <td style="width: 48%; vertical-align: top;">&#160;</td>
          <td colspan="1" style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 18%; vertical-align: top;">&#160;</td>
        </tr>

    </table>
    <div><br>
    </div>
    <br>
    <div>
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"> </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>brhc10039577_ex5-1.htm
<DESCRIPTION>EXHIBIT 5.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using Broadridge PROfile 22.7.2.5062
         Copyright 1995 - 2022 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
    <div>
      <div style="text-align: right; font-weight: bold;">Exhibit 5.1</div>
      <div><br>
      </div>
      <div>July 22, 2022</div>
      <div><br>
      </div>
      <div>ADMA Biologics, Inc.</div>
      <div>465 State Route 17</div>
      <div>Ramsey, NJ 07446</div>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top;">RE:</td>
            <td style="width: auto; vertical-align: top;">
              <div><u>ADMA Biologics, Inc., Post-Effective Amendment to Registration Statements on Form S-8</u></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div>Ladies and Gentlemen:</div>
      <div>&#160;</div>
      <div style="text-indent: 36pt;">We have acted as counsel to ADMA Biologics, Inc., a Delaware corporation (the &#8220;<u>Company</u>&#8221;), in connection with the filing of the Company&#8217;s Post-Effective Amendment No. 1 (the &#8220;<u>Post-Effective Amendment</u>&#8221;) to
        the Registration Statements on Form S-8 (File Nos. 333-263345, 333-254770, 333-237658, 333-229921, 333-224492, 333&#8209;220058 and 333-204590) (collectively, the &#8220;<u>Original Registration Statements</u>&#8221;) under the Securities Act of 1933, as amended
        (the &#8220;<u>Act</u>&#8221;), with the Securities and Exchange Commission (the &#8220;<u>SEC</u>&#8221;) relating to the registration by the Company of the offer and sale of up to an aggregate 20,963,208 shares of the Company&#8217;s common stock, par value $0.0001 per share
        (the &#8220;<u>Common Stock</u>&#8221;) that were previously registered under the Amended and Restated ADMA Biologics, Inc. 2014 Omnibus Incentive Compensation Plan, as amended (the &#8220;<u>2014 Plan</u>&#8221;).</div>
      <div>&#160;</div>
      <div style="text-indent: 36pt;">On June 21, 2022 (the &#8220;<u>Effective Date</u>&#8221;), the Company&#8217;s stockholders approved the ADMA Biologics, Inc. 2022 Equity Compensation Plan (the &#8220;<u>2022 Plan</u>&#8221;). Following the approval of the 2022 Plan, no future
        awards will be granted under the 2014 Plan and (a) up to 5,714,620 shares of Common Stock (which reflects the number of shares of Common Stock that remained available for grants under the 2014 Plan as of the Effective Date) and (b) shares of Common
        Stock subject to awards outstanding as of the Effective Date under the 2014 Plan (to the extent such shares of Common Stock are, or become no longer issuable under the 2014 Plan and instead are, or become, issuable under the 2022 Plan) (the shares
        described under (a) and (b) together, the &#8220;<u>Rollover Shares</u>&#8221;) shall be available for issuance under the 2022 Plan.</div>
      <div>&#160;</div>
      <div style="text-indent: 36pt;">In connection with this opinion letter, we have examined the Post-Effective Amendment, the Original Registration Statements and originals, or copies certified or otherwise identified to our satisfaction, of (i) the
        Second Amended and Restated Certificate of Incorporation of the Company, as amended to date (ii) the Amended and Restated Bylaws of the Company, as amended to date, (iii) certain resolutions of the Company&#8217;s Board of Directors relating to the
        Post-Effective Amendment, (iv) the 2014 Plan, (v) the 2022 Plan and (vi) such other documents, records and other instruments as we have deemed appropriate for purposes of the opinion set forth herein.</div>
      <div>&#160;</div>
      <div style="text-indent: 36pt;">We have assumed the genuineness of all signatures, the legal capacity of all natural persons, the authenticity of the documents submitted to us as originals, the conformity with the originals of all documents submitted
        to us as certified, facsimile or photostatic copies and the authenticity of the originals of all documents submitted to us as copies. With respect to matters of fact relevant to our opinions as set forth below, we have relied upon certificates of
        officers of the Company, representations made by the Company in documents examined by us, and representations of officers of the Company. We have also obtained and relied upon such certificates and assurances from public officials as we have deemed
        necessary for the purposes of our opinions set forth below.</div>
      <div>&#160;</div>
      <div style="text-indent: 36pt;">Subject to the foregoing and the other matters set forth herein, we are of the opinion, as of the date hereof, that the Rollover Shares have been duly authorized by the Company and, when issued by the Company in
        accordance with the provisions of the 2022 Plan, will be validly issued, fully paid and non-assessable.</div>
      <div>&#160;</div>
      <div style="text-indent: 36pt;">The opinions expressed herein are limited to the federal laws of the United States and the Delaware General Corporation Law.</div>
      <div>&#160;</div>
      <div style="text-indent: 36pt;">We hereby consent to the use of this opinion as Exhibit 5.1 to the Post-Effective Amendment.&#160; In giving such consent, we do not hereby admit that we are acting within the category of persons whose consent is required
        under Section 7 of the Act or the rules or regulations of the SEC thereunder.</div>
      <div>&#160;</div>
      <div>
        <table cellspacing="0" cellpadding="0" border="0" id="z0c6161df6a3f4a518d4b7c2866a88d84" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

            <tr>
              <td style="width: 50.00%;">
                <div>&#160;</div>
              </td>
              <td style="width: 50.00%;">
                <div>Very truly yours,</div>
              </td>
            </tr>
            <tr>
              <td style="width: 50.00%;">
                <div>&#160;</div>
              </td>
              <td style="width: 50.00%;">
                <div>&#160;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 50.00%;">
                <div>&#160;</div>
              </td>
              <td style="width: 50.00%;">
                <div>/s/ Morgan, Lewis &amp; Bockius LLP</div>
              </td>
            </tr>

        </table>
      </div>
      <div><br>
      </div>
    </div>
    <div><br>
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"> </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>3
<FILENAME>brhc10039577_ex23-2.htm
<DESCRIPTION>EXHIBIT 23.2
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using Broadridge PROfile 22.7.2.5062
         Copyright 1995 - 2022 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
    <div>
      <div>Exhibit 23.2</div>
      <div><br>
      </div>
      <div style="text-align: center;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</div>
      <div><br>
      </div>
      <div style="text-align: justify;">We consent to the incorporation by reference in the Post-Effective Amendment No.1 to the following Registration Statements:</div>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z7f137b38ab274392b61d9a428f8b5fc1">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">(1)</td>
            <td style="width: auto; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">Registration Statement (Form S-8 No. 333-204590) on May 29, 2015 to register 1,600,000 shares of Common Stock,</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z1dfa8154b7d74959ad3c16b6a889fa6a">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">(2)</td>
            <td style="width: auto; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">Registration Statement (Form S-8 No. 333-220058) on August 18, 2017 to register 2,000,000 shares of Common Stock,</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z510730dfebb140299ff4ff4cf6ef83e4">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">(3)</td>
            <td style="width: auto; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">Registration Statement (Form S-8 No. 333-224492) on April 27, 2018 to register 1,812,666 shares of Common Stock,</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z0f3e4825b962497687393b0666a7542e">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">(4)</td>
            <td style="width: auto; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">Registration Statement (Form S-8 No. 333-229921) on February 27, 2019 to register 1,854,122 shares of Common Stock,</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z0e89cc0587f04946966da8b681fcee5d">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">(5)</td>
            <td style="width: auto; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">Registration Statement (Form S-8 No. 333-237658) on April 13, 2020 to register 2,372,734 shares of Common Stock,</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za50a57daf50f47edbf4ff445ff62b07b">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">(6)</td>
            <td style="width: auto; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">Registration Statement (Form S-8 No. 333-254770) on March 26, 2021 to register 3,491,134 shares of Common Stock, and</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z0a669c2902d941ea985337680d2067bd">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">(7)</td>
            <td style="width: auto; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">Registration Statement (Form S-8 No. 333-263345) on March 7, 2022 to register 7,832,552 shares of Common Stock;</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div>of our report dated March 24, 2022, on our audits of the consolidated financial statements of the Company as of December 31, 2021 and 2020 and for the years then ended, which report is included in the Annual Report on Form 10-K of the Company
        for the year ended December 31, 2021.</div>
      <div><br>
      </div>
      <div>/s/ CohnReznick LLP</div>
      <div><br>
      </div>
      <div>Holmdel, New Jersey</div>
      <div>July 22, 2022</div>
      <div><br>
      </div>
      <div><br>
      </div>
      <div>
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
